finanzen.net
19.02.2019 18:59
Bewerten
(0)

Top Research Reports for United Parcel Service, Morgan Stanley & CME Group

DRUCKEN
Tuesday, February 19, 2019The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including United Parcel Service (UPS), Morgan Stanley (MS) and CME Group (CME). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>United Parcel Service’s shares have outperformed the Zacks Transportation - Air Freight and Cargo industry over the past year, gaining +5.9% vs. -7.5%. The Zacks analyst likes UPS' efforts to reward shareholders through dividends and buybacks. In 2018, the company rewarded shareholders to the tune of $4.2 billion through the aforementioned shareholder-friendly measures. Continuing its pro-investor approach, in February 2019, UPS increased its quarterly dividend by 5.5% to 96 cents per share. Robust free cash flow generation by UPS supports the possibility of a dividend hike going forward as well. E-commerce growth is an added positive at UPS and it aided the company's fourth-quarter 2018 results similar to the past few quarters. The company anticipates cross-border e-commerce volume to grow by 28% over the next three years. However, the company's high capital expenditures are limiting bottom-line growth. Trade-war related tensions and high debts pose further challenges to the company.(You can read the full research report on United Parcel Service here >>>).Shares of Morgan Stanley have lost -2.5% over the past three months, underperforming the Zacks Investment Banking industry, which has gained +2.1% over the same period. The company possesses an impressive earnings surprise history, having beaten expectations in three of the trailing four quarters.The Zacks analyst thinks its efforts to strengthen wealth management business (organically and through acquisitions), focus on corporate lending, steady loan growth, higher interest rates and normalized levels of trading activities will likely aid revenues. Also, the company’s steady capital deployment activities reflect a strong balance sheet position. However, a slowdown in debt originations will hinder underwriting fee income growth. Further, mounting operating expenses is a major near-term concern for the company.(You can read the full research report on Morgan Stanley here >>>).CME Group’s shares have underperformed the Zacks Securities and Exchanges industry over the past year, losing -8.7% versus -5.7%. CME Group’s fourth-quarter earnings per share beat estimates and improved year over year. The quarter witnessed increased volatility and higher customer demand for diverse risk management products, which drove strong trading volumes of more than 20 million contracts per day. The Zacks analyst thinks the company remains well-poised for growth on a strong market position with varied derivative product lines. Efforts to expand and cross sell its core exchange-traded business via new product initiatives and a global reach are positives. It intends to focus more on over-the-counter clearing services on interest rate swaps as well as foreign exchange. Also, the buyout of Nex Group will help CME Group generate $200 million in run-rate cost synergies, annually, by 2021-end. Also, the company targets 1x debt-to-EBITDA by 2020 end. However, escalating expenses are putting pressure on margins.(You can read the full research report on CME Group here >>>).Other noteworthy reports we are featuring today include Fiserv (FISV), Williams Companies (WMB) and Enbridge (ENB).Is Your Investment Advisor Fumbling Your Financial Future?See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”Click to get it free >>Mark Vickery Senior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Friday, February 19, 2019The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including United Parcel Service (UPS), Morgan Stanley (MS) and CME Group (CME). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>>United Parcel Service’s shares have outperformed the Zacks Transportation - Air Freight and Cargo industry over the past year, gaining +5.9% vs. -7.5%. The Zacks analyst likes UPS' efforts to reward shareholders through dividends and buybacks. In 2018, the company rewarded shareholders to the tune of $4.2 billion through the aforementioned shareholder-friendly measures. Continuing its pro-investor approach, in February 2019, UPS increased its quarterly dividend by 5.5% to 96 cents per share. Robust free cash flow generation by UPS supports the possibility of a dividend hike going forward as well. E-commerce growth is an added positive at UPS and it aided the company's fourth-quarter 2018 results similar to the past few quarters. The company anticipates cross-border e-commerce volume to grow by 28% over the next three years. However, the company's high capital expenditures are limiting bottom-line growth. Trade-war related tensions and high debts pose further challenges to the company.(You can read the full research report on United Parcel Service here >>> Today's Must Read Dividends & Buybacks Buoy UPS Amid Cost Woes Acquisitions to Support Morgan Stanley (MS), Expenses a Woe Growing Volumes Aid CME Group (CME), Rising Expenses Worrying Featured Reports Enbridge (ENB) to Gain From C$16B Midstream Project Backlog The Zacks analyst thinks that Enbridge will continue to earn stable fee-based revenues from its C$16-billion backlog of midstream energy projects. Williams (WMB) Buoyed by Brazos Midstream JV Amid High Debt While the newly Brazos Midstream JV will enhance Williams' exposure to the lucrative Permian Basin, the Zacks analyst is worried over the considerable long-term debt load. Fiserv (FISV) Rides on Strategic Business Moves, Debt High The Zacks analyst is impressed with Fiserv's strategy to widen its client base and enhance its product portfolio with the help of buyouts and partnerships. Bakken Play Aids Marathon (MRO) Amid International Weakness The Zacks analyst is worried about turnaround activities in the Equatorial Guinea region. CDW Benefits From Robust Growth in Customer End Markets Per the Zacks analyst, CDW's broad-based product and solutions portfolio is boosting growth across its customer markets, which include corporate, small business, government, education and healthcare. Inorganic Growth, Rising Top-line Aid WellCare Health (WCG) Per the Zacks analyst, a number of buyouts such as Meridian Health Plans of Michigan and Illinois and MeridianRx have led to its growth, which in turn, has boosted its revenues. Segmental Momentum, Cost Cuts Aid Avery Dennison (AVY) Per the Zacks analyst, productivity initiatives, pricing action and solid segment performance aided by growth in emerging markets and acquisitions bode well for Avery Dennison. New Upgrades Celldex's (CLDX) Immuno-Oncology Pipeline Progress Promising Per the Zacks analyst, Celldex has several promising immuno-oncology candidates which are in early to mid-stage development for several cancer indications including the lucrative lung cancer. Improving Leasing, Occupier Outsourcing to Drive CBRE (CBRE) Per the Zacks analyst, CBRE Group will gain from improving occupier outsourcing business, leasing and strategic acquisitions. Also, digital and technology investments will give it a comparative edge. Fresenius Medical (FMS) Gains Ground on NxStage Acquisition Fresenius Medical's acquisition of NxStage Medical currently favors the company. The Zacks Analyst is optimistic about the company's Cura buyout in past. New Downgrades Competition in DNA Sequencing Market Ails Pacific (PACB) The Zacks analyst believes cutthroat competition in the DNA sequencing market is a headwind for Pacific Biosciences. Sluggishness in services and other revenue segments is a woe. Dependence on Rubraca Weighs on Clovis Oncology (CLVS) Per the Zacks analyst, although the company is progressing well with label expansion of Rubraca, sales are not improving even as competition rises. Dependence on sole drug is a concern. Intercept's (ICPT) Dependence on Ocaliva Worrying Per the Zacks analyst, while the uptake of Ocaliva is encouraging, Intercept's dependence on a single drug for growth is a concern as any negative news would adversely impact its growth prospects. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Williams Companies, Inc. (The) (WMB): Free Stock Analysis Report United Parcel Service, Inc. (UPS): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Fiserv, Inc. (FISV): Free Stock Analysis Report Enbridge Inc (ENB): Free Stock Analysis Report CME Group Inc. (CME): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Weiter zum vollständigen Artikel bei "Zacks"
Quelle: Zacks

Nachrichten zu Morgan Stanley

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Morgan Stanley

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
18.04.2019Morgan Stanley OutperformRBC Capital Markets
04.04.2019Morgan Stanley HoldHSBC
02.01.2019Morgan Stanley Equal WeightBarclays Capital
10.09.2018Morgan Stanley overweightJP Morgan Chase & Co.
20.07.2018Morgan Stanley NeutralGoldman Sachs Group Inc.
18.04.2019Morgan Stanley OutperformRBC Capital Markets
10.09.2018Morgan Stanley overweightJP Morgan Chase & Co.
12.06.2018Morgan Stanley overweightJP Morgan Chase & Co.
15.03.2018Morgan Stanley overweightJP Morgan Chase & Co.
20.11.2017Morgan Stanley overweightJP Morgan Chase & Co.
04.04.2019Morgan Stanley HoldHSBC
02.01.2019Morgan Stanley Equal WeightBarclays Capital
20.07.2018Morgan Stanley NeutralGoldman Sachs Group Inc.
19.07.2018Morgan Stanley HoldSociété Générale Group S.A. (SG)
22.01.2018Morgan Stanley HoldSociété Générale Group S.A. (SG)
20.01.2016Morgan Stanley SellSociété Générale Group S.A. (SG)
25.07.2011Morgan Stanley underperformRBC Capital Markets
02.10.2009Morgan Stanley underperformCalyon Securities Inc.
31.08.2005Morgan Stanley underweightPrudential Financial
28.07.2005Morgan Stanley underweightPrudential Financial

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Morgan Stanley nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX geht fester ins Oster-Wochenende -- Gewinnmitnahmen bei Wirecard-Aktie -- Pinterest-Aktie mit fulminantem Börsendebüt -- Daimler, Senvion, Deutsche Post, OSRAM, Zoom-IPO im Fokus

Apple nimmt zweite Roboter-Linie zum iPhone-Recycling in Betrieb. PUMA-Aktionäre segnen Aktiensplit ab. Samsung nimmt Falt-Handy wegen möglicher Mängel unter die Lupe. 3,4 Milliarden Dollar: Cannabis-Megadeal in Nordamerika eingefädelt. Nestlé: Robuster Start ins neue Geschäftsjahr. US-Versicherer Travelers steigert Gewinn.

Die 5 beliebtesten Top-Rankings

Die beliebtesten Arbeitgeber in Deutschland
Hier gibt es die beliebtesten Jobs
Die zehn größten Kapitalvernichter
Hier wurde am meisten Anlegergeld verbrannt
DIe innovativsten Unternehmen
Diese Unternehmen sind am fortschrittlichsten
Das hat sich geändert
Diese Aktien hat George Soros im Depot
Diese Aktien hat Warren Buffett im Depot
Einige Änderungen unter den Top-Positionen
mehr Top Rankings

Umfrage

Wirtschaftsminister Peter Altmaier (CDU) sieht sich derzeit starker Kritik ausgesetzt. Zu Recht?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Apple Inc.865985
TeslaA1CX3T
Alphabet A (ex Google)A14Y6F
Facebook Inc.A1JWVX
Intel Corp.855681
Netflix Inc.552484
TwitterA1W6XZ
GoProA1XE7G
Deutsche Bank AG514000
Wirecard AG747206
Daimler AG710000
Scout24 AGA12DM8
Amazon906866
Allianz840400
CommerzbankCBK100